Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › S-1

S-1

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of S-1

9 trials tracked of S-1: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 685 citations.

9Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Phase 2 6 Phase 1 2
  1. Phase 3 Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) Completed · 685 cited
  2. Phase 2 A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma Completed
  3. Phase 2 Capecitabine Versus S-1 in Elderly Advanced Gastric Cancer (AGC): Randomized Trial Completed
  4. Phase 2 Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer Completed
  5. Phase 2 Capecitabine vs. S-1 in Unresectable or Recurrent Breast Cancer Completed
  6. Phase 2 A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1 Completed
Show 3 more trials
  1. Phase 2 Phase 2 Study of S-1 in Advanced or Metastatic Pancreatic Cancer Completed
  2. Phase 1 Study Of Sunitinib With S-1 And Cisplatin For Gastric Cancer Completed
  3. Phase 1 A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer Completed

Showing the 9 most-cited and recently-updated of 9 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
SIB-RT plus S-1 improves survival in elderly inoperable esophageal cancer
ENT (Otolaryngology) RCT
SIB-RT plus S-1 improves survival in elderly inoperable esophageal cancer Combination therapy improves survival in older esophageal cancer patients
This phase III multicenter RCT compared simultaneous integrated boost radiotherapy plus oral S-1 (CRTCT) to radiotherapy alone in patients a…
Adding chemo to radiation boosts 5-year survival from 24% to 34% in older patients with inoperable esophageal cancer.
May 1, 2026
S-1 plus oxaliplatin consolidation shows low toxicity in stage II/III lower rectal cancer patients
Oncology Phase I
S-1 plus oxaliplatin consolidation shows low toxicity in stage II/III lower rectal cancer patients First study reports SOX consolidation for lower rectal cancer
This Phase I study enrolled 12 patients with stage II/III lower rectal adenocarcinoma.
A small early trial found SOX chemotherapy was safe after radiation for lower rectal cancer, with surgery completed on time for all patients…
May 1, 2026
Case report describes sintilimab-associated toxic epidermal necrolysis in gastric carcinoma patient
Oncology Sys. Review
Case report describes sintilimab-associated toxic epidermal necrolysis in gastric carcinoma patient Rare Skin Reaction Follows Successful Stomach Cancer Therapy
This case report details a patient with gastric carcinoma developing delayed-onset toxic epidermal necrolysis during neoadjuvant sintilimab …
A new case shows a common stomach cancer drug can cause dangerous skin reactions even after surgery.
Frontiers Apr 22, 2026
Subcutaneous PEG-rhG-CSF reduced grade ≥3 neutropenia and CIN in GI cancer patients receiving oral chemotherapy
Oncology RCT
Subcutaneous PEG-rhG-CSF reduced grade ≥3 neutropenia and CIN in GI cancer patients receiving oral chemotherapy New Shot Cuts Severe Low White Blood Cell Risk
This prospective, single-center, open-label, exploratory, non-randomized controlled study evaluated subcutaneous PEG-rhG-CSF in 43 gastroint…
A simple shot given before chemotherapy could keep your body's infection-fighting cells strong when taking oral cancer pills.
Frontiers Apr 16, 2026
Serplulimab with FOLFOX showed disease control in AFP-producing gastric adenocarcinoma with liver metastases
Allergy & Immunology Cohort
Serplulimab with FOLFOX showed disease control in AFP-producing gastric adenocarcinoma with liver metastases Rare Stomach Cancer Shrinks After New Combo Treatment
This case report and literature review describes a 67-year-old man with AFP-producing gastric adenocarcinoma and liver metastases treated wi…
A rare stomach cancer that spread to the liver shrank dramatically when doctors combined standard chemotherapy with a newer immune-boosting …
Frontiers Apr 16, 2026